Nanjing Sanhome Pharmaceutical Co., Ltd.

Liwen Zhao

Yong Wang

Hongyan Chen

Di Zhang

Cang Zhang

Xian Zhang

Sheng Bi

Chunhuan Jiang

Guochuang Zheng

Yiping Gao

Xu Quan

Dezhong Wang

Yang Nan

Hai Feng Wang

Yan Mei Zhang

Hai Jun Wang

Yazhou Wang

Yang Liu

Yan Zhang

Chao Li

Qi Liu

Xiaorong Liu

Chen Wang

Yongqiang Zhu

Feng Wu

Haiping Zhou

Dandan Huang

Liang Jin

Yanan Zhang

Hongbin Chen

Xinsheng Shi

Hongfeng Gu

Menghua Chen

Silin Pang

Qifeng Song

Wei Hai

Wenming Wu

Yexin Liao

Bingyang Ge

Luwei Han

Shengwei Yang

Wei Sun

Qiqi Shi

Tingting Yang

Yuxiu Li

Kangning Zhan

Hai Wang

The present invention belongs to the field of medicinal chemistry and relates to a class of substituted tricyclic compounds as PRMT5 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (A) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, a preparation method therefor, a pharmaceutical composition containing the compounds, and the use of the compounds or the composition for treating a disease mediated by PRMT5. The compounds of the present invention show significant inhibitory activity on PRMT5.

Substituted tricyclic compound as PRMT5 inhibitor and use thereof

The present disclosure relates to the technical field of antibody drugs, and in particular, to an anti-CD47 antibody or an antigen-binding fragment thereof, a pharmaceutical composition comprising the anti-CD47 antibody or the antigen-binding fragment thereof, and applications thereof. The anti-CD47 antibody or the antigen-binding fragment thereof has significant antitumor activity and high affinity with human CD47 protein, can eliminate the capability of SIRPa to bind to CD47 on a surface of a cell, and does not have significant hemoagglutination activity and thus can be applied to the preparation of an anti-tumor drug.

Anti-CD47 antibody and application thereof

Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. 

Compound as ACC inhibitor and use thereof

Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.

Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof

A novel nucleoside phosphoramidate compound of the formula below, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection, and having a good anti-HCV effect; a pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof: 

Nucleoside phosphoramidate compound and use thereof

The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof

In the field of pharmaceutical chemistry compounds of general formula I having heteroaryl alkynyl moiety or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, and pharmaceutical compositions including these compounds, as well as uses of these compounds and compositions thereof in the manufacture of a medicament. The compounds have a strong inhibitory effect on BCR-ABL tyrosine kinase and are useful for treating diseases, such as tumors. 

Heteroaryl alkyne compound and use thereof

Growing community of inventors

Nanjing, China

Liwen Zhao